In fact, some of the approved MS therapies, including Glatiramer Acetate [61,62], FTY720 [63] and IFN-β [64], are capable of reducing Th17 responses in both experimental autoimmune encephalomyelitis models [61,62] and in patients with multiple sclerosis [63,64]. Here, IFNB1 is linked to myeloid sarcoma.